CTOs on the Move

Freenome

www.freenome.com

 
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.freenome.com
  • 259 East Grand Avenue Suite 3434
    South San Francisco, CA USA 94080
  • Phone: 831.704.6883

Executives

Name Title Contact Details

Funding

Freenome raised $65M on 03/01/2017
Freenome raised $160M on 07/24/2019
Freenome raised $270M on 08/26/2020

Similar Companies

Allcells LLC

Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMotiv

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.

Scrippshealth

Scrippshealth is a Lajolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Minute Molecular Diagnostics

Minute Molecular Diagnostics was founded in 2017 as a spinout of the Northwestern University Center for Innovation in Global Health Technology (CIGHT). Comprised of a strong management team with extensive diagnostic industry experience, the company has raised $8 million in funding from the NIH and Diagnostic Industry Executives.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.